Business

Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results

Press Release – No. 3 / 2026 Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results Copenhagen, Denmark, February 12, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that it will host a conference call on February 19, 2026, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the full year of 2025. Participating in the call

articleZealand Pharma A/sFebruary 12, 20262/company/zealand-pharma-as-1/news/zealand-pharma-conference-call-on-february-19-at-2pm-cet-8am-et-to-present-full-year-2025-financial-results
Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results

About this update from Zealand Pharma A/s

[{"type":"image","alt":"Zealand Pharma","displaySize":"","headline":null,"caption":"Zealand Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":121,"url":"https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6gUCOEdJjLHihlE.VvDQtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff","width":300,"height":121}},"lazy":false},{"type":"text","content":"Press Release – No. 3 / 2026","length":28,"tagName":"p"},{"type":"text","content":"Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results","length":109,"tagName":"p"},{"type":"text","content":"Copenhagen, Denmark, February 12, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that it will host a conference call on February 19, 2026, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the full year of 2025.","length":349,"tagName":"p"},{"type":"text","content":"Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will be followed by a Q&A session.","length":232,"tagName":"p"},{"type":"text","content":"The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at https://edge.media-server.com/mmc/p/23mcfcxf. To receive telephone dial-in information and a unique personal access PIN, please register at https://register-conf.media-server.com/register/BI21d42ba397554c7088d1911aa7cea23e. Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on Zealand Pharma’s website at https://www.zealandpharma.com/investors/events-presentations/.","length":599,"tagName":"p"},{"type":"text","content":"About Zealand Pharma A/S","length":24,"tagName":"p"},{"type":"text","content":"Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D ex...

More updates from Zealand Pharma A/s

Zealand Pharmabiotechnology companyDavid KendallChief Executive OfficerChief Medical OfficerAdam SteensbergChief Financial Officer